Thermo Fisher ups IVD offering with $470m Brahms buy
This article was originally published in Clinica
Executive Summary
Thermo Fisher Scientific is to grow its in vitro diagnostics portfolio by acquiring German biomarkers firm Brahms for €330m ($470m).